Otonomy Suspends Development of Lead Drug After Phase III Flop, Stock Plunges Post author:Sam Post published:August 29, 2017 Post category:BioPharma August 30, 2017By Alex Keown, BioSpace… Source: BioSpace You Might Also Like Spark's Good Week Continues With Signing of Huge Lease Near HQ December 7, 2017 Eli Lilly Dealt Another Setback as Lung Cancer Drug Flunks Phase III Test October 9, 2017 Novartis AG Boss Updates Q2 Financials and Reaffirms M&A Strategy July 18, 2017
